~~<i id='6E214CBA95'><strike id='6E214CBA95'><tt id='6E214CBA95'><pre id='6E214CBA95'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

entertainment

author：focus 2025-09-28 23:56:41 - browse：94

For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

Editas Medicine, the winner of that battle in the U.S., will now cash in.

Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Petition to FDA: Get the lead out of consumer hair dyes

focus

hotspot

Wikipedia

explore

hotspot

focus

MedicareisathemeattheAMAmeetingtakingplacejustsouthofWashington.BrittanyTrang/STATWASHINGTON–TheAmer

WSS

Cancer diagnosis changes perspective doctor, former hospital CEO

HCA discloses massive data breach affecting 11 million patients

Charles Manson follower Leslie Van Houten released from prison after 53 years

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Weight loss drugs should be covered by insurers, AMA says

What is STAT's opinion section for?

knowledge

entertainment

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Living with Fabry disease, a condition that causes chronic pain

23andMe had bad news about my health. I wish a person had delivered it

NIH fellows want a pay raise. Will that mean less money for grants?

What does generative AI mean for health care? We asked experts

How the political right came to back psychedelics to treat trauma

Apple is now the first public company to be valued at $3 trillion

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

State Dept. review finds Biden bears some blame for Afghanistan failures

Study suggests Covid rebound is far more common with Paxlovid than without

hotspot

Medical school prerequisites are outdated

A letter from the executive editor: STAT UnitedHealth investigation

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Why ADHD is under

Why ADHD is under

Wikipedia

explore

hotspot

focus